GSK: Promacta improved platelet count in late-stage study

12/7/2008 | Reuters

GlaxoSmithKline reported data from a Phase III trial showing that patients who received Promacta, an FDA-approved treatment for chronic immune thrombocytopenic purpura, had an eight-times greater chance of having a prolonged increase in blood-platelet count compared with those who took a placebo. The study also found that Promacta increased the risk of liver problems but did not cause serious liver damage, GSK said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY